| Target Price | $8.16 |
| Price | $4.01 |
| Potential |
103.49%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Adial Pharmaceuticals, Inc. 2027 .
The average Adial Pharmaceuticals, Inc. target price is $8.16.
This is
103.49%
register free of charge
$11.55
188.03%
register free of charge
$6.06
51.12%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Adial Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adial Pharmaceuticals, Inc. stock has an average upside potential 2027 of
103.49%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -11.93 | -4.01 |
| 82.46% | 66.39% | |
| P/E | negative |
6 Analysts have issued a Adial Pharmaceuticals, Inc. forecast for earnings per share. The average Adial Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Adial Pharmaceuticals, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Alliance Global Partners |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| LUCID CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Rodman & Renshaw |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Alliance Global Partners:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
LUCID CAPITAL MARKETS:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
Nov 14 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


